Financials in USD. Standardized financial statements.
A compact view of how T2 Biosystems, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $7.19M | $22.30M | $28.06M | $18.13M | $8.34M | $10.50M | $4.67M | $4.08M | $2.81M | $119,000 |
| Revenue Growth? | -67.8% | -20.5% | +54.8% | +117.5% | -20.6% | +125.0% | +14.4% | +45.0% | +2263.9% | 0.0% |
| Cost of Revenue? | $15.36M | $21.14M | $20.70M | $21.28M | $16.76M | $15.40M | $12.03M | $6.87M | $1.74M | $19.78M |
| Gross Profit? | -$8.17M | $1.17M | $7.36M | -$3.15M | -$8.43M | -$4.90M | -$7.36M | -$2.79M | $1.07M | -$19.66M |
| Gross Margin? | -113.6% | +5.2% | +26.2% | -17.4% | -101.1% | -46.7% | -157.8% | -68.4% | +38.1% | -16523.5% |
| Operating Expenses? | $41.49M | $56.68M | $50.33M | $38.21M | $43.63M | $40.19M | $46.49M | $48.09M | $44.46M | $30.80M |
| Operating Income? | -$49.66M | -$54.05M | -$42.97M | -$41.36M | -$52.06M | -$45.09M | -$53.85M | -$50.88M | -$43.38M | -$30.68M |
| EBITDA? | -$43.88M | -$54.87M | -$41.13M | -$36.71M | -$48.30M | -$41.96M | -$50.58M | -$48.43M | -$41.86M | -$29.98M |
| Income Before Tax | -$50.08M | -$62.00M | -$49.24M | -$46.80M | -$59.01M | -$51.15M | -$62.43M | -$54.80M | -$45.29M | -$31.39M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $42,000 |
| Net Income? | -$50.08M | -$62.00M | -$49.24M | -$46.80M | -$59.01M | -$51.15M | -$62.43M | -$54.80M | -$45.29M | -$31.39M |
| EPS? | $-19.19 | $-1222.14 | $-1549.82 | $-1928.54 | $-6934.20 | $-126.12 | $-194.29 | $-210.66 | $-220.91 | $-361.85 |
| Diluted EPS? | $-19.19 | $-1222.14 | $-1549.82 | $-1928.54 | $-6934.20 | $-126.12 | $-194.29 | $-210.66 | $-220.91 | $-361.85 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality